To evaluate the incidence, baseline characteristics, and clinical prognosis of blood-brain barrier (BBB) disruption after endovascular therapy in acute ischemic stroke patients.
A total of 220 ...patients treated with endovascular therapy between April 2007 and October 2011 were identified from a prospective, clinical, thrombolysis registry. All patients underwent a nonenhanced CT scan immediately after treatment. CT scan or MRI was systematically realized at 24 hours to assess intracranial hemorrhage complications. BBB disruption was defined as a hyperdense lesion on the posttreatment CT scan.
BBB disruption was found in 128 patients (58.2%; 95% confidence interval CI, 51.4%-64.9%). Cardioembolic etiology, high admission NIH Stroke Scale score, high blood glucose level, internal carotid artery occlusion, and use of combined endovascular therapy (chemical and mechanical revascularization) were independently associated with BBB disruption. Patients with BBB disruption had lower rates of early major neurologic improvement (8.6% vs 31.5%, p < 0.001), favorable outcome (39.8% vs 61.8%, p = 0.002), and higher rates of 90-day mortality (34.4% vs 14.6%, p = 0.001) and hemorrhagic complications (42.2% vs 8.7%, p < 0.001) than those without BBB disruption. By multivariable analysis, patients with BBB disruption remained with a lower rate of early neurologic improvement (adjusted odds ratio OR, 0.28; 95% CI, 0.11-0.70) and with a higher rate of mortality (adjusted OR, 2.37; 95% CI, 1.06-5.32) and hemorrhagic complications (adjusted OR, 6.38; 95% CI, 2.66-15.28).
BBB disruption has a detrimental effect on outcome and is independently associated with mortality after endovascular therapy. BBB disruption assessment may have a role in prognosis staging in these patients.
Summary Background The efficacy of intravenous (IV) alteplase is restricted by the speed of recanalisation and the site of the occlusion. The aim of this study was to ascertain the effect of a ...combined IV–endovascular approach (intra-arterial alteplase and, if required, additional thrombectomy) in patients with stroke due to arterial occlusion. Methods We compared recanalisation rates, neurological improvement at 24 h, and functional outcome at 3 months between two periods (February, 2002, to March, 2007, vs April, 2007, to October, 2008) in patients in a prospective registry who were treated with different regimens of alteplase within 3 h of symptom onset. Patients with confirmed occlusion who were treated before April, 2007, were treated with IV alteplase; after April, 2007, patients were treated with a systematic IV–endovascular approach. Analysis was by intention to treat. Findings 46 (87%) of 53 patients treated with the IV–endovascular approach achieved recanalisation versus 56 (52%) of 107 patients in the IV group (adjusted relative risk RR 1·49, 95% CI 1·21–1·84; p=0·0002). Early neurological improvement (NIHSS score of 0 or 1 or an improvement of 4 points or more at 24 h) occurred in 32 (60%) patients in the IV–endovascular group and 42 (39%) patients in the IV group (adjusted RR 1·36, 0·97–1·91; p=0·07). Favourable outcome (mRS of 0–2 at 90 days) occurred in 30 (57%) patients in the IV–endovascular group and 47 (44%) patients in the IV group (adjusted RR 1·16, 0·85–1·58; p=0·35). The mortality rate at 90 days was 17% in both groups, and symptomatic intracranial haemorrhage was reported in five (9%) patients in the IV–endovascular group and in 12 (11%) patients in the IV group. Better clinical outcome was associated with recanalisation in both groups and with time to recanalisation in the IV–endovascular group. Interpretation An IV–endovascular approach is associated with higher recanalisation rates than is IV alteplase in patients with stroke and confirmed arterial occlusion. In patients treated with an IV–endovascular approach, a shorter time from symptom onset to recanalisation is associated with better clinical outcomes. Funding SOS-ATTAQUE CEREBRALE.
To assess the potential therapeutic effect of intratendinous injection of platelet-rich plasma (PRP) under ultrasound (US) guidance to treat tendon tears and tendinosis in a pilot study with ...long-term follow-up.
The study included 408 consecutive patients referred for treatment by PRP injection of tendinopathy in the upper (medial and lateral epicondylar tendons) and the lower (patellar, Achilles, hamstring and adductor longus, and peroneal tendons) limb who received a single intratendinous injection of PRP under US guidance. Clinical and US data were retrospectively collected for each anatomic compartment for upper and lower limbs before treatment (baseline) and 6 weeks after treatment. Late clinical data without US were collected until 32 months after the procedure (mean, 20.2 months). The McNemar test and regression model were used to compare clinical and US data.
QuickDASH score, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score, and residual US size of lesions were significantly lower after intratendinous injection of PRP under US guidance at 6 weeks and during long-term follow-up compared with baseline (P < .001 in upper and lower limb) independent of age, gender, and type of tendinopathy (P > .29). No clinical complication was reported during follow-up.
Intratendinous injection of PRP under US guidance appears to allow rapid tendon healing and is well tolerated.
To prospectively determine whether early first-pass perfusion and delayed-enhancement magnetic resonance (MR) imaging sequences can enable differentiation of acute myocardial infarction (AMI) from ...myocarditis in patients with acute chest pain.
All examinations were performed according to guidelines of the institutional board on medical ethics and clinical investigation and after informed patient consent was obtained. Fifty-five patients with a clinical presentation suggestive but not typical of AMI were examined. At final diagnosis, 31 patients had AMI and 24 had myocarditis. At-rest MR imaging was performed and included first-pass perfusion and delayed-enhancement sequences. Three independent observers read each image data set separately and then in consensus. The main abnormalities included first-pass perfusion defects and delayed highly enhancing areas. The numbers and distributions of involved segments and the transmural extents and the shapes of the highly enhancing areas were noted. For comparisons between the AMI and myocarditis patient groups, the chi2 test was used to assess the locations of the abnormalities and the Mann-Whitney U test was used to assess the numbers of involved segments. The final diagnoses were obtained with coronary angiography as the reference standard for the AMI group and on the basis of normal coronary angiographic findings and the spontaneous resolution of clinical symptoms and wall motion abnormalities for the myocarditis group.
MR imaging patterns were significantly different between the two cardiac disease groups (P < .05). All the patients with AMI had a segmental early subendocardial defect, with corresponding segmental subendocardial or transmural delayed high enhancement in a predominantly anteroseptal or inferior vascular distribution in 28 patients. All patients with AMI had stenosis of at least the infarct-affected coronary artery. All but one of the patients with myocarditis had no early defect and focal or diffuse nonsegmental nonsubendocardial delayed enhancement predominantly in an inferolateral location.
Use of combined early- and late-perfusion MR imaging sequences helps to distinguish AMI from myocarditis.
Background: Preoperative assessment of patients with aortic valve stenosis (AS) relies on the evaluation of AS severity (aortic valve area, AVA) and left ventricular ejection fraction (LVEF) by ...echocardiography, and of coronary artery anatomy by coronary angiography. Aim: To evaluate the feasibility and accuracy of contrast-enhanced multidetector computed tomography (MDCT), as a single non-invasive preoperative test, for simultaneous evaluation of the AVA, LVEF and coronary status in patients with AS. Methods: 40 consecutive patients with AS scheduled for aortic valve replacement underwent transthoracic echocardiography, electrocardiogram (ECG)-gated MDCT and coronary angiography within a time span of 1 week. Results: MDCT measurements could be performed in all patients. A good correlation but a slight overestimation was observed between mean (SD) AVA measured by MDCT and by echocardiography (0.87 (0.22) vs 0.81 (0.20) cm2, p = 0.01; r = 0.77, p<0.001). Mean difference between methods was 0.06 (0.15) cm2. LVEF measured by MDCT correlated well with, and did not differ from, electrocardiographic measurements (59% (13%) vs 61% (10%), p = 0.34; r = 0.76, p<0.001; mean difference 1% (8%)). Coronary angiography displayed 33 lesions in 13 patients. MDCT correctly identified 26 of these 33 lesions and overestimated three <50% stenosis. On a segment-by-segment analysis, MDCT sensitivity, specificity, positive and negative predictive values were 79%, 99%, 90% and 98%, respectively. For each patient, MDCT had a sensitivity of 85% (11/13 patients), a specificity of 93% (25/27 patients) and positive and negative predictive values of 85% (11/13 patients) and 93% (25/27 patients), respectively. Conclusion: MDCT can provide a simultaneous and accurate evaluation of the AVA, LVEF and coronary artery anatomy in patients with AS. In the near future, with technological improvements, MDCT could achieve an exhaustive and comprehensive preoperative assessment of patients with AS. In addition, for the assessment of AS severity in difficult cases, MDCT could be considered as an alternative to transoesophageal echocardiography or cardiac catheterisation.
Objectives
To assess the potential of intra-tendinous injection of platelet rich plasma (PRP) to treat tendinosis (T+) in a rat model of patellar and Achilles T+, and evaluate its local toxicity.
...Methods
Thirty rats (120 patellar and Achilles tendons) were used. We induced T+ into 80 tendons (patellar = 40, Achilles = 40) by injecting collagenase at day 0 under ultrasound (US) guidance. Clinical examination and US at day 3, followed by US-guided intra-tendinous injection of either PRP (PRPT+,
n
= 40) or physiological serum (ST+,
n
= 40, control). Follow-up was at days 6, 13, 18 and 25 using clinical, US and histological evaluation. To study PRP toxicity, we injected PRP into 40 normal tendons (PRPT-) and compared with 40 untreated normal tendons (T-).
Results
All PRPT+ showed better joint mobilisation compared with ST+ at day 6 (
P
= 0.005), day 13 (
P
= 0.02), day 18 (
P
= 0.003) and day 25 (
P
= 0.01). Similar results were found regarding US and histology, with smaller collagen fibre diameters (day 6,
P
= 0.003, day 25,
P
≤ 0.004), less disorganisation and fewer neovessels (day 6,
P
= 0.003, day 25,
P
= 0.0003) in PRPT+ compared with ST+. Comparison between PRPT- and T- showed no PRP toxicity (
P
= 0.18).
Conclusions
Our study suggests that mono-injection of PRP in T+ improves tendon healing, with no local toxicity.
Key Points
• We assessed the potential of platelet rich plasma (PRP) to treat tendinosis.
• We treated patellar and Achilles tendinosis in a rat model.
• We evaluated clinical, imaging and histological data.
• Intra-tendinous PRP injection could be useful in the treatment of tendinosis.
Paramedian pontine infarct (PPI) is usually attributed to basilar artery (BA) atherosclerosis. However, this hypothesis has thus far been supported only by post-mortem studies. The authors show that ...high-resolution MRI is a promising method that can detect BA plaques in patients with PPI at or near the origin of the penetrating artery, whereas MR angiograms may appear normal.
Cerebrospinal fluid (CSF) pulsations result from change of blood volume in the closed craniospinal cavity. We used cine phase contrast MR analysis to determine whether spinal CSF pulsations result ...from spinal vascular pulsations or intracranial subarachnoid pulsations, whether intracranial CSF pulsations result from intracranial large arteries pulsations or cerebrovascular bed changes. We performed a quantified physiological mapping of CSF velocity waveforms along the craniospinal axis. Thirty-six volunteers participated in the study. MR acquisitions were obtained at the intracranial level, the upper, midcervical, cervicothoracic, mid thoracic, and/or the thoracolumbar levels. The temporal velocity information were plotted as wave form and key temporal parameters were determined and analyzed; intervals from the R wave to the onset of CSF systole, to CSF systolic peak, to the end of systole, as well as duration of systole. Three kinds of dynamic channels could be differentiated along the spinal axis, the lateral, medioventral and mediodorsal channels. Lateral spinal CSF pulse waves show significant craniocaudal propagation. No such significant progression was detected through the medial channels along the spine. Through the medial channels, a cephalic progression was observed from the upper cervical level to the intracranial level. At the craniocervical junction, mediodorsal CSF systole appeared the earliest one whereas in the anterior intracranial basal cistern, CSF systole appeared delayed. In conclusion, spinal CSF pulsations seem to result mainly from intracranial pulsations in the lateral channels, whereas local vascular pulsations could modify CSF pulse wave mainly in the medial channels. At the craniocervical junction, our results suggest that blood volume change in the richly vascularised cerebellar tonsils is the main initiating factor of CSF systole; and that spinal vascular pulsations could be considered as an additional early and variable CSF pump.
PDF
